Dro Spaz

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dro Spaz

Quick Facts

Property Description
Active Ingredient Drotaverine (as hydrochloride)
Pharmacological Class Antispasmodic (PDE4 Inhibitor)
Form Tablet (Oral), Solution for Injection (Parenteral)
Origin Synthetic (Isoquinoline derivative)
General Purpose Relieve smooth muscle cramps and associated pain

What Kind of Medicine is Dro Spaz?

Dro Spaz is an antispasmodic medication primarily used to relieve pain and discomfort caused by the tightening and cramping of smooth muscles within the body. Its active ingredient is Drotaverine (INN), a Papaverine derivative used for functional gastrointestinal disorders.

Dro Spaz belongs to the pharmacological class of antispasmodics (or spasmolytics). Unlike general pain relievers (analgesics), this medicine is designed to act directly on the muscle to stop the involuntary spasm itself. Drotaverine is used for the relief of abdominal pain caused by muscle spasms. The medicine is produced internationally, and in certain regions, the tablets may be available without a prescription.

Composition, Origin, and Available Forms

The active substance in Dro Spaz is Drotaverine, a synthetic chemical compound structurally related to papaverine. Drotaverine is an isoquinoline derivative and works by inhibiting the phosphodiesterase-4 (PDE4) enzyme.

Dro Spaz is supplied in two primary pharmaceutical preparations: the widely used oral tablets and a sterile solution for injection (ampoules). The availability of both the tablet and the injection form is a feature that allows healthcare professionals to choose the administration route best suited to the patient's need for immediate smooth muscle spasm relief.

What is the General Purpose of Dro Spaz?

The general therapeutic purpose of Dro Spaz is to help quickly alleviate the discomfort associated with internal muscle cramps. The medication works by promoting relaxation in the smooth muscles that line the walls of internal organs, such as those in the digestive and biliary systems. This specific action counters the spasms that are often the underlying source of colicky or cramping pain.


What side effects are possible with Dro Spaz?

Possible Side Effects and Safety Information

The safety profile of Dro Spaz (drotaverine hydrochloride) is primarily characterized by a low incidence of adverse reactions during standard therapeutic use. Regulatory documents categorize most unwanted effects as Rare (occurring in 1 to 10 users in 10,000).

Commonly Documented Adverse Reactions (Rare)

System Organ Class Effects
Nervous System Headache, dizziness, sleep disturbances
Gastrointestinal Nausea, constipation
Cardiac/Vascular Palpitations, hypotension, hot flash
Skin/Immune System Rash, itching, allergic reactions

Serious Adverse Reactions and Overdose

While well-tolerated at recommended doses, inadvertent high intake (overdose) may lead to serious events. Documented consequences include a significant decrease in blood pressure (hypotension), cardiac rhythm and conduction disorders, and the potential for collapse or respiratory depression.

Key Safety Precautions and Contraindications

The medication is strictly contraindicated in patients with severe liver, kidney, or heart diseases, specifically including AV block II and III degree and cases of pronounced hypotension or shock (systolic blood pressure below 90 mmHg). Caution is advised when using this medicine, particularly in the first trimester of pregnancy. Use during breast-feeding is generally not recommended due to a lack of sufficient safety data. Due to the potential for dizziness or vertigo linked to possible hypotension, patients are advised to exercise caution and avoid operating machinery or driving if these side effects occur.

Overdose and Emergency Response

Drotaverine overdose involves a range of officially documented clinical presentations and potentially severe systemic risks. Manifestations reported in regulatory documents include systemic effects such as weakness, malaise, dizziness, headache, vomiting, and pronounced sleepiness. The most critical concerns involve the cardiovascular system, where documented severe outcomes include heart rhythm and conduction disorders, a substantial drop in blood pressure (hypotension), the development of a potentially fatal complete bundle block, and ultimately, cardiac arrest.

Regulatory labeling is explicit: an individual must contact a doctor immediately or seek immediate medical attention upon suspected accidental or intentional overdose, given the life-threatening cardiac risks. Treatment is strictly defined as symptomatic and supportive, as no specific antidote is known for Drotaverine. Due to the high risk of severe cardiac complications, official documents state that continuous monitoring and hospital observation are required. Management procedures may include steps like gastric lavage and other methods to reduce the absorption of the ingested drug as part of the supportive care protocol.

Therapeutic Uses of Dro Spaz

What Dro Spaz Treats: Main Uses and Benefits

Dro Spaz is an antispasmodic medication applied in addressing symptoms related to physical discomfort and symptoms related to heightened physiological activity. The medication is considered relevant for easing symptoms that create noticeable functional strain.

This medication is used to help with symptoms associated with acute or disruptive episodes, particularly in conditions involving episodic or fluctuating manifestations. It is applied in scenarios where additional management of discomfort is required, specifically for symptomatic relief in gastrointestinal complaints, biliary tract disorders, urinary tract issues, and gynecological disorders such as dysmenorrhea.

The medication helps address symptom clusters that may become intense or disruptive, providing supportive relief when symptoms interfere with routine activities, and contributes to improved comfort during periods of heightened symptoms.

“The medication supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.”

Quick Fact: Support for Smooth Muscle Spasms

Regulatory References

  1. Swiss Public Assessment Report for Spaverin

Eligibility and Restrictions for Use

Dro Spaz (Drotaverine) is subject to strict eligibility rules defined by regulatory authorities to ensure patient safety. The official profile classifies populations into three categories: contraindicated, not recommended, and those requiring caution.

Populations for Whom Use is Contraindicated

This medication must not be used if a patient has a known hypersensitivity to Drotaverine or any of its excipients. Absolute contraindications also apply to individuals with severe hepatic impairment, severe renal impairment, or severe heart failure.

Age-related rules formally contraindicate the use of Dro Spaz in children under 6 years of age. For the tablet formulation, patients with rare hereditary metabolic conditions such as galactose intolerance or lactase deficiency are also excluded.

Restricted and Conditional Use

Use is generally not recommended during pregnancy or lactation due to insufficient safety data documented in official labeling. Additionally, patients with Parkinson’s disease taking Levodopa should avoid use, as Drotaverine may reduce the effectiveness of that medication.

Caution is specifically required for patients with hypotension (low blood pressure) and those with mild to moderate hepatic or renal impairment, requiring careful assessment before administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Drotaverine (the active ingredient in Dro Spaz) primarily documents several significant pharmacodynamic interactions with co-administered medicinal products.

Drug-Drug Interactions

A critical interaction is documented with Levodopa, the co-administration of which may decrease its intended antiparkinsonian effect. This pharmacodynamic outcome is formally stated to result in an increase in the patient’s rigidity and tremor.

Co-administration with agents that lower blood pressure, such as antihypertensive agents, may intensify the hypotensive effect due to an additive action. This caution specifically includes drugs such as Tricyclic Antidepressants, Quinidine, and Procainamide. Furthermore, Drotaverine is documented to intensify the effects of other spasmolytic agents when used concurrently.

Certain substances may alter the drug’s processing or effectiveness. Magnesium Hydroxide is documented as a substance that may increase the absorption of Drotaverine. Additionally, Phenobarbital is noted in regulatory sources to improve the spasm removal reliability of Drotaverine.

Restrictions and Cautions

Consumption of alcohol is formally restricted by regulatory authorities and should be avoided, as co-administration may cause increased dizziness. Although no specific drug-drug contraindications are explicitly listed, caution is advised for patients with severe hepatic or renal impairment due to the extensive hepatic metabolism and renal excretion pathway of the drug.

Mechanism of Action

Drotaverine, the active component, operates by functioning as a selective inhibitor of Phosphodiesterase Type 4 (PDE4), an enzyme responsible for degrading the cellular messenger, cyclic adenosine monophosphate (cAMP). This primary interaction results in a prolonged and elevated level of cAMP, initiating a cascade that drives smooth muscle relaxation. The increased concentration of cAMP activates Protein Kinase A (PKA), which then functionally deactivates Myosin Light Chain Kinase (MLCK). Since MLCK is required for the final step of smooth muscle contraction, its inactivation leads to the physiological consequence of spasmolysis** in visceral smooth muscle tissue.

Additionally, Drotaverine exhibits an ancillary effect by functioning as a minor blocker of Voltage-dependent L-type Calcium Channels. By slightly limiting the influx of calcium ions ( Ca^2+), which are essential for muscle excitation, this mechanism modulates the contractile state within the pathways, functioning alongside its main action and contributing to the overall spasmolytic effect.

Dosage and Administration Information

The administration of Dro Spaz (drotaverine) is characterized by specific routes, dosing schedules, and age-specific limitations. The medication is formulated for oral use as tablets (40 mg or 80 mg) and as a solution for injection (20 mg/mL) for intramuscular (IM) or intravenous (IV) administration.


Administration Schedule and Routes

Entity Principle
Routes Oral (Tablet), Intramuscular (IM), Intravenous (IV) injection.
Adult Oral Dosing Daily total is typically 120 mg to 240 mg.
Dose Frequency The total daily oral dose is generally administered in 2 to 3 separate, divided doses.
Parenteral Use The injection dose is administered in 1 to 3 applications per day, requiring professional supervision.
Special Condition The intravenous injection must be administered slowly as a procedural constraint.

Use in Specific Populations

Dose maximums are identified for pediatric groups:

  • Children 6 to 12 years: Maximum daily oral intake of 80 mg.
  • Children over 12 years: Maximum daily oral intake of 160 mg.

A divided daily dosing schedule is used for the oral form to maintain the daily range. The option for parenteral administration is reserved for acute scenarios requiring rapid action and clinical oversight, where the injection must be administered slowly. If a dose is missed, the standard practice is to resume the next scheduled administration without taking a double dose.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence for Chronic Neuropathic Pain

Research examined the drug's effect in models relevant to neuropathic pain. Clinical trials evaluated whether the drug influenced chronic neuropathic pain over a specific duration. These studies primarily focused on adults with peripheral neuropathy of mixed etiology.

  • Study Design: The main research consisted of randomized, double-blind, placebo-controlled trials.
  • Primary Findings: Research examined whether the drug influenced measures of nerve function and pain scores. One large trial reported a statistically significant difference in mean pain scores between the group receiving the drug and the group receiving placebo after eight weeks.
  • Long-term Data: Follow-up data collected over six months was analyzed to assess the maintenance of the observed effects.

Safety Profile and Tolerability

The clinical data includes studies that evaluated the drug's effect on target symptoms and reviewed reported side effects. Research compared the drug to placebo, evaluating differences in reported side effects.

The most frequently reported side effects in the main trials included:

  • Dizziness
  • Drowsiness
  • Headache

Limitations of Current Research

While initial research has provided data on pain score changes, evidence remains limited regarding its use in specific patient populations, such as those with pre-existing kidney or liver impairment. It is not yet clear whether the drug offers any benefit to patients whose condition has not responded to other forms of management. The data does not contain information on off-label uses.

Key Studies & References

  1. Pharmacologic therapies for neuropathic pain: an assessment of reporting biases in randomized controlled trials
  2. DRO SPAZ 40 mg tablets (Patient Information Leaflet/Regulatory Monograph)
  3. Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (NCT00143156)

Frequently Asked Questions (FAQ)

Common questions about Dro Spaz (FAQ)

Q: Does Dro Spaz treat muscle pain or only spasms?

Dro Spaz is an antispasmodic, which means its main action is to cause relaxation in smooth muscle that is cramping. Official product information indicates that the medicine is primarily used to relieve pain and discomfort caused by the tightening and cramping of smooth muscles. Therefore, the pain relief is secondary to the drug’s action in stopping the underlying spasm.

Q: Are there any specific foods or drinks to avoid while taking Dro Spaz?

Regulatory documents explicitly restrict the consumption of alcohol while taking this medicine because co-administration may increase the risk of dizziness. While no specific dietary foods are generally listed to avoid, any concerns about food or drink consumption with this medicine can be discussed with a healthcare provider.

Q: What if I accidentally take two doses of Dro Spaz close together?

The existing section on 'How to use Dro Spaz' describes the protocol for missed doses, which is to resume the next scheduled administration without taking a double dose. This instruction is defined to support adherence to the administration schedule outlined in the official labeling.

Q: How quickly can a person expect Dro Spaz to start working?

Studies examining the movement of the drug in the body (pharmacokinetics) indicate that Dro Spaz typically reaches its highest concentration in the bloodstream approximately 45 to 60 minutes after a person takes it orally. This measure relates to the time when the drug is most available to exert its effects.

Q: Is it okay to take Dro Spaz with standard pain relievers like acetaminophen?

Drotaverine, the active component, is available in combination formulations with acetaminophen (paracetamol) in some regions. The existence of these combination products indicates that co-administration is not strictly contraindicated. A healthcare provider is the resource for determining the safety of concurrent medication use.

Q: Is there a difference in effectiveness between the tablet and liquid forms of Dro Spaz?

The official documentation describes the injection (liquid) form as being reserved for acute scenarios where rapid action is required, while the tablet is used for general daily dosing. The injection form is designated for acute scenarios requiring rapid action, which distinguishes its intended use from the standard oral tablet.

Q: Can Dro Spaz interact with common herbal supplements like St. John's Wort?

Official regulatory documents acknowledge a general need for caution regarding the combination of Dro Spaz with any herbal supplements or other over-the-counter products. This general caution is noted because potential interactions may not always be explicitly listed in the formal product information.

Q: What is the typical duration of effect for a single dose of Dro Spaz?

Pharmacokinetic studies have examined the time it takes for the drug to leave the body, known as the elimination half-life, which is documented to be between 7 and 16 hours. This prolonged presence supports the design of a multiple-times-daily dosing schedule.

Q: Is Dro Spaz the same class of drug as other 'spasm' medications I have heard of?

Dro Spaz is officially classified as a Papaverine derivative and belongs to the general antispasmodic pharmacological class, distinguishing it from other types of pain relievers or muscle relaxants.

Q: Are there any mental or mood changes that studies have linked to Dro Spaz?

Adverse reactions affecting the nervous system that have been reported include headache, dizziness, and sleep disturbances (such as insomnia). Specific changes in mood are not typically listed in the core regulatory summary of side effects.

Q: Why do some people report Dro Spaz causing dry mouth?

Although dry mouth is not listed in every regulatory summary, it has been noted as a potential adverse reaction in certain official documents. A healthcare provider is the appropriate resource to discuss any side effect a patient experiences.

Q: What does 'contraindication' mean in the context of Dro Spaz?

A contraindication is a medical term for a condition or circumstance where the drug must not be used. For Dro Spaz, this is typically because the risk of a serious or adverse outcome is considered to clearly outweigh any potential benefits for the patient.

Q: Are there any specific tests a doctor should run before prescribing Dro Spaz?

Given that the medicine is strictly contraindicated in cases of severe liver or kidney impairment, the patient’s organ status is typically considered as part of the assessment prior to administration. This practice supports compliance with the drug’s required safety profile.

Q: Do studies suggest that Dro Spaz works better for one type of spasm over another?

Regulatory indications list the drug's approved use for smooth muscle spasms associated with both biliary tract disorders and urinary tract disorders. This suggests the medicine is recognized for its utility across multiple internal smooth muscle systems.

Q: What is the difference between Dro Spaz and a general muscle relaxant?

Dro Spaz is a selective smooth muscle relaxant and is documented to be free of the side effects associated with anticholinergic antispasmodics. It primarily targets the muscles of internal organs, not skeletal muscles.

Q: Is it true that Dro Spaz should not be taken with certain anxiety medications?

The official documents note that Dro Spaz may intensify the blood pressure-lowering effect of certain medications, including certain classes of antidepressants that are also prescribed for anxiety. Any potential interaction is a topic for discussion with a healthcare professional.

Q: Why is Dro Spaz sometimes described as having anticholinergic effects?

Regulatory monographs actually state that Drotaverine acts directly on smooth muscle and does not affect the autonomic nervous system. This means the drug is documented to be free of the side effects, such as dry mouth and blurred vision, commonly associated with traditional anticholinergic antispasmodics.

Q: How should Dro Spaz be handled if a person has certain medical conditions like glaucoma?

Since the drug is documented to work directly on smooth muscle without affecting the autonomic nervous system, some regulatory sources indicate that it can be used in patients with medical conditions such as glaucoma.

Q: What are the primary differences between Dro Spaz and other drugs for similar conditions?

The main distinguishing feature of Dro Spaz is its mechanism of action: it is a selective PDE4 inhibitor that targets the spasms of smooth muscle, such as those that line the internal organs. This makes its action highly targeted compared to some other general muscle relaxants.

Q: Do experts recommend a specific time of day to take Dro Spaz?

Official labeling instructs that the daily dosage should be taken in 2 to 3 divided doses, but it does not specify a particular time of day. While the label only specifies a schedule of divided doses, some clinical studies administering the drug have utilized an administration time of 1 hour before a meal in their protocols.

How should Dro Spaz be stored and disposed of?

The storage and disposal instructions for Dro Spaz (drotaverine) are set by regulatory documents to maintain product quality and ensure safety.


Storage Requirements

  • Temperature: Both the tablets and solution for injection must be stored at a temperature below 30°C.
  • Protection: The solution for injection is required to be stored in a place protected from light.
  • Packaging: Tablets must be stored in their original package.
  • Safety: The medicine must be kept out of the reach and sight of children.
  • Stability: Do not use the medicine after the expiry date.

Disposal

Official instructions prohibit throwing the medicine away via wastewater or household waste. Patients must ask their pharmacist how to properly dispose of unused or expired Dro Spaz to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dro Spaz found in:

A-Z Index: